Oventus extends markets during Covid-19 pandemic
Sleep apnoea device manufacturer Oventus sales have returned to the pre-Covid-19 pandemic trajectory, with its devices now being fitted at 15 ‘lab in lab’ sites across the global sleep market. Revenue in the latest quarter was up 192 per cent on the previous corresponding period to $248,000. With the virus subduing patient throughput, the company is moving to open new labs offering to measure and fit the devices, and piloting a homecare business model. The Oventus device is worn in the mouth at night keeping the breathing passages open, and is seen as an alternative to the positive airways pressure apnoea treatment model.
Droneshield raises $17 million from investors
Drone countermeasure manufacturer Droneshield has raised what it described as a transformative $17 million from investors. The cash will help the company scale up to meet orders from European, US and Australian customers, including $5.2 million in firm orders on hand. The company is also evolving its technology from the counter-drone field into a broader AI and electronic warfare capability.
Emvision device successfully detect and classify stroke in patients
Emvision’s device to detect stroke has completed a pilot clinical trial involving 30 patients suffering ischaemic and haemorrhagic stroke. The device, which utilises electronic microwave imaging, was tested at the Princess Alexandra Hospital in Brisbane and was able to classify stroke type with an overall accuracy of between93.3 and 96 per cent. Positive feedback was received from operators and patients.
Imagion Biosystems raises cash from investors
Imaging technology developer Imagion Biosystems has successfully raised $4.7 million after costs in an oversubscribed placement of funds. The cash will complete a Phase 1 study of its MagSense HER2 breast cancer detection system. The company is developing its non-radioactive diagnostic imaging system which combines biotechnology and nanotechnology.
Drought hits cotton ginning
Drought in eastern Australia has severely impacted throughput at Namoi Cotton’s 12 regional gins located in cotton producing areas. Ginning volumes to 31 August were down by 330,000 bales or 73 per cent on the previous corresponding period. The company ginned 120,000 bales in the first half of FY21, the lowest recorded seasonal volume in Namoi’s recent history.
Picture: Namoi Cotton
Subscribe to our free @AuManufacturing newsletter here.